A note from our friends at Reagan Gold Group_SS(ad) The 401(k) Move Most Americans Don’t Know About Your 401(k) provider…
Trump’s next equity target may be hiding near $5
A note from our friends at The Oxford Club(ad) Dear reader, Most investors wait for the government press conference. I…
Nvidia Sold a Quarter of Its Intel Stake. That’s a Verdict.
Nvidia's Q3 13F shows a big Intel trim, and the market noticed.
One BDC Worth Buying While the Sector Sells Off
BC Partners bought a BDC at 90% of NAV. Not every discount is worth chasing.
Target years worth of trading gains in mere days?
A note from our friends at Media Pub(ad) Let’s be real for a second. While most traders are still squinting…
Nvidia Is Down 30% From Its Peak. Tuesday Is the First Test.
Few earnings events in recent memory carry this many simultaneous inputs. Nvidia (NVDA) reports fiscal Q3 2027 results on Tuesday,…
SLL: Because Billions Could Pour into the Market that Day
November 16, 2026 Bonus Content: China’s October Miss: What It Means for Copper and Ore A note from our friends…
Washington Can Fix Its Books With Gold. Not Dollars.
A note from our friends at Newmont Capital_MP(ad) There is a monetary shift building that retirement savers will not see…
Democrats have won but the risks remain
A note from our friends at Weiss Ratings(ad) Dear Reader, Democrats have won both the House and the Senate. That…
Summit Therapeutics Paid $500 Million for Ivonescimab. The FDA Just Said No.
The rejection of Summit's lung cancer drug tests every Western thesis on Chinese oncology assets.
